P
olymyxin antibiotics are considered a last line of defense in the treatment of severe infections caused by multidrug-resistant and extensively drug-resistant Gram-negative pathogens. However, the recent discovery of the plasmid-mediated polymyxin antibiotic resistance gene mcr-1 and its apparent diffusion into environmental, food animal, and retail food sources and clinical settings threaten to stem the clinical utility of polymyxin antibiotics (1) (2) (3) (4) (5) . The mcr-1 gene encodes a phosphoethanolamine transferase which modifies lipid A in the outer membranes of Enterobacteriaceae, leading to decreased binding affinities of polymyxin antibiotics (1, 6) .
Since there exists the possibility that modification of the outer membrane of Gram-negative bacteria has a more general effect on antibiotic susceptibility, the in vitro activity of the novel fluorocycline antibiotic eravacycline was evaluated against a diverse set of mcr-1-positive Escherichia coli clinical (n ϭ 16) and animal (n ϭ 1) isolates, Salmonella enterica animal isolates (n ϭ 4), and a set of 4 carbapenem-resistant clinical isolates comprised of E. coli, Enterobacter cloacae, and Klebsiella pneumoniae engineered to overexpress the mcr-1 gene.
Susceptibility to eravacycline and comparators was evaluated by broth microdilution MIC assays performed according to Clinical and Laboratory Standards Institute (CLSI) methodology (7) . Antibiotics were obtained from Sigma-Aldrich (St. Louis, MO). The set of 21 nonclonal strains tested, carrying the mcr-1 gene either chromosomally or on one of four different plasmids, was collected from sources in Switzerland (n ϭ 5), South Africa (n ϭ 7), France (n ϭ 3), Portugal (n ϭ 4), and the Centers for Disease Control (CDC0346, CDC349 [http://www.cdc.gov/drugresistance/resistance -bank/currently-available.html]; n ϭ 2) and included representatives from at least 14 sequence types. The presence of the mcr-1 gene was confirmed using published PCR primers and methods (1) . The eravacycline MIC 50 and MIC 90 values against this panel were 0.25 and 0.5 g/ml, respectively, similar to values for the in-class comparator tigecycline (Table 1) . Nine isolates were resistant to 3rd-and/or 4th-generation cephalosporins, and 19 were resistant to tetracycline. The MIC 50 and MIC 90 values for colistin were 8 and 16 g/ml, respectively, and those for polymyxin B were 4 and 8 g/ml, respectively; 20/21 isolates showed MIC values of Ն4 g/ml for colistin and/or polymyxin B.
To evaluate the specific effects of mcr-1 expression in the absence of other resistance determinants that may be present in naturally occurring mcr-1-positive clinical isolates (8), the mcr-1 gene was PCR amplified from mcr-1-positive isolate Af23 (9) using the forward and reverse primers GCGCGGTCATGATGCAGCATAC TTCTGTGTG and GCGGCCTCGAGTCAGCGGATGAATGCG GTG, with additions of 5= BspHI and 3= XhoI cloning sites, respectively. The mcr-1 sequence was confirmed to be identical to that of GenBank accession number KX032519. The mcr-1 gene was cloned into the NcoI and XhoI cloning sites of the pBAD B -gentamicin vector under the control of an arabinose-inducible promoter, similar to what has previously been reported (6 methodology, with the exception that both gentamicin and arabinose were present. Results showed that while overexpression of mcr-1 in each clinical isolate raised the MIC values for colistin and polymyxin B by 32-to 64-fold, there was no effect on susceptibility to eravacycline and other comparators (i.e., MIC values with and without mcr-1 overexpression were within 2-fold of those of the lacZ control strain) ( Table 2 ). It was noted that the MIC values of the cell wall-inhibiting antibiotics meropenem, cefepime, ceftazidime, and cefotaxime for plasmid-containing strains (expressing either lacZ or mcr-1) generally were lower (when endpoints were available) than those for the corresponding "no-plasmid" controls. Since similar MIC values were obtained for strains expressing either lacZ or mcr-1, the lower MIC values may be attributed to general effects on growth rate due to recombinant expression or antibiotic interactions due to the presence of gentamicin in assays with the plasmid-containing strains.
In conclusion, the present study showed that eravacycline was potent in vitro against naturally occurring mcr-1-positive bacterial isolates and unaffected by the overexpression of mcr-1 in Enterobacteriaceae. 
